We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+49.04%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$18.8B
AUM Growth
+$4.11B
Cap. Flow
-$554M
Cap. Flow %
-2.95%
Top 10 Hldgs %
85.02%
Holding
117
New
8
Increased
21
Reduced
10
Closed
18

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$227M
2
DBVT
DBV Technologies
DBVT
+$72.8M
3
KOD icon
Kodiak Sciences
KOD
+$69.2M
4
KRRO icon
Korro Bio
KRRO
+$19.2M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$15.7M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$627M
2
AMRN
Amarin Corp
AMRN
+$134M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$72.9M
4
NGNE icon
Neurogene
NGNE
+$39.4M
5
CBAY
Cymabay Therapeutics
CBAY
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.59%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
51
Cabaletta Bio
CABA
$442M
$8.89M 0.05%
+636,363
New +$7.54M
NXTC icon
52
NextCure
NXTC
$21M
$8.45M 0.04%
12,500
– –
ACGN
53
DELISTED
Aceragen Inc
ACGN
$8.39M 0.04%
271,376
– –
RETA
54
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$8.38M 0.04%
+40,983
New +$7.48M
SGMO
55
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.37M 0.04%
999,823
– –
PTGX icon
56
Protagonist Therapeutics
PTGX
$8.74B
$8.28M 0.04%
1,174,282
– –
MIRM icon
57
Mirum Pharmaceuticals
MIRM
$6.7B
$8.17M 0.04%
333,333
– –
ABEO icon
58
Abeona Therapeutics
ABEO
$355M
$7.48M 0.04%
91,529
+40,000
+78% +$2.82M
FLGT icon
59
Fulgent Genetics
FLGT
$566M
$7.35M 0.04%
569,444
+444,444
+356% +$5.28M
IFRX icon
60
InflaRx
IFRX
$253M
$7.04M 0.04%
1,778,415
– –
ALBO
61
DELISTED
Albireo Pharma Inc
ALBO
$6.36M 0.03%
250,000
– –
CNST
62
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$6.28M 0.03%
133,333
– –
MTNB icon
63
Matinas BioPharma
MTNB
$1.8M
$5.97M 0.03%
52,647
+12,948
+33% +$750K
ARAV
64
DELISTED
Aravive, Inc. Common Stock
ARAV
$5.92M 0.03%
433,333
-230,755
-35% -$2.04M
TPST icon
65
Tempest Therapeutics
TPST
$14.3M
$5.62M 0.03%
+4,274
New +$6.03M
ORTX
66
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.58M 0.03%
40,570
– –
CPRX
67
DELISTED
Catalyst Pharmaceutical
CPRX
$5.03M 0.03%
1,341,902
– –
SYRS
68
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.77M 0.03%
69,017
-28,467
-29% -$1.73M
EVFM
69
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$4.67M 0.02%
50,454
+43,651
+642% +$3.68M
NGM
70
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$4.62M 0.02%
250,000
– –
MTEM
71
DELISTED
Molecular Templates, Inc.
MTEM
$4.43M 0.02%
21,115
+4,166
+25% +$599K
CRNX icon
72
Crinetics Pharmaceuticals
CRNX
$8.88B
$4.39M 0.02%
175,000
– –
YMAB
73
DELISTED
Y-mAbs Therapeutics
YMAB
$4.33M 0.02%
138,514
+35,714
+35% +$1.06M
MRKR icon
74
Marker Therapeutics
MRKR
$19.3M
$4.32M 0.02%
150,000
– –
BLUE
75
DELISTED
bluebird bio
BLUE
$3.51M 0.02%
3,088
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, Baker Bros. Advisors held 117 positions worth $18.8B, up 28% from $14.7B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q4 2019 filing shows 8 new, 21 increased, 10 reduced and 18 closed positions. Its largest new stake was Exact Sciences: 2,585,791 shares worth $239M. The largest sale was Genomic Health, Inc., an estimated $627M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Financials and Technology.

  • Baker Bros. Advisors's largest Q4 2019 buy was Exact Sciences: 2,585,791 shares worth $239M.
  • Baker Bros. Advisors added most to DBV Technologies in Q4 2019, an estimated $72.8M increase.
  • Baker Bros. Advisors's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $134M.
  • Baker Bros. Advisors fully exited Genomic Health, Inc. in Q4 2019, selling an estimated $627M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $18.8B portfolio in Q4 2019.
  • Baker Bros. Advisors opened 8 new positions and closed 18 in Q4 2019.
  • Baker Bros. Advisors's portfolio value rose 28% quarter-over-quarter to $18.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.